Research Findings Animal studies suggest BPC-157 may: Support nervous system function Promote tissue healing Influence neurotransmitter systems Support gut health The Gut-Brain Connection Researchers increasingly recognize the relationship between gut health and mental wellness
the latter explanation is suggested by our results (see Fig
Review your caloric intake, as the medication reduces appetite but does not prevent weight gain if calorie consumption remains excessive
As the breast skin relaxes, the nipple and areola may sit lower on the chest
Blood tests to assess glucose control, kidney function, electrolytes, thyroid function, and nutritional markers (such as vitamin B12, iron studies, and complete blood count) may be appropriate depending on your clinical presentation and risk factors
Serious injuries and symptoms discussed in Wegovy and GLP-1 litigation may include: Gastroparesis or delayed gastric emptying Stomach paralysis symptoms, including nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down Ileus or intestinal blockage Bowel obstruction or pseudo-obstruction Persistent vomiting and dehydration Malnutrition or inability to tolerate normal food intake Severe abdominal pain requiring emergency care or hospitalization Pancreatitis, which has been reported as a risk signal in GLP-1 research NAION-related vision loss, which should be evaluated separately from gastrointestinal injury claims These allegations do not mean every patient who used Wegovy has a claim